Whanin Pharm Total Assets
Whanin Pharm total assets. Based on the latest financial reports, Whanin Pharm (016580) holds total assets worth ₩482.63 Billion KRW (≈ $327.07 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Whanin Pharm for the company's overall valuation and market capitalisation.
Total Assets of Whanin Pharm (2009–2025)
Total assets of Whanin Pharm from 2009 to 2025. This chart illustrates how Whanin Pharm's total assets have evolved over time, based on quarterly financial data. See today's stock price for Whanin Pharm for real-time trading data and today's change.
Whanin Pharm - Asset Composition Analysis
Whanin Pharm Total Assets Breakdown (December 2025)
Whanin Pharm total assets breakdown as of December 2025. Whanin Pharm's total assets of ₩482.63 Billion consist of 47.7% current assets and 52.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 13.3% |
| Accounts Receivable | ₩61.88 Billion | 12.9% |
| Inventory | ₩96.32 Billion | 20.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩9.29 Billion | 1.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Whanin Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Whanin Pharm current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Whanin Pharm's current assets represent 47.7% of total assets in 2025, a decrease from 81.4% in 2009.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 26.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 20.1% of total assets.
Whanin Pharm Competitors by Total Assets
Key competitors of Whanin Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Whanin Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.26 | 4.91 | 9.37 |
| Quick Ratio | 2.48 | 2.82 | 8.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩183.73 Billion | ₩163.36 Billion | ₩206.40 Billion |
Whanin Pharm - Advanced Valuation Insights
This section examines the relationship between Whanin Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 12.8% |
| Total Assets | ₩478.89 Billion |
| Market Capitalization | $130.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Whanin Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Whanin Pharm's assets grew by 12.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Whanin Pharm (2009–2025)
The table below shows the annual total assets of Whanin Pharm from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩478.89 Billion ≈ $324.54 Million |
+12.76% |
| 2024-12-31 | ₩424.71 Billion ≈ $287.82 Million |
+5.85% |
| 2023-12-31 | ₩401.23 Billion ≈ $271.91 Million |
+8.62% |
| 2022-12-31 | ₩369.37 Billion ≈ $250.32 Million |
+4.58% |
| 2021-12-31 | ₩353.19 Billion ≈ $239.35 Million |
+7.17% |
| 2020-12-31 | ₩329.56 Billion ≈ $223.34 Million |
+8.09% |
| 2019-12-31 | ₩304.88 Billion ≈ $206.62 Million |
+5.98% |
| 2018-12-31 | ₩287.69 Billion ≈ $194.96 Million |
+4.68% |
| 2017-12-31 | ₩274.84 Billion ≈ $186.25 Million |
+12.90% |
| 2016-12-31 | ₩243.44 Billion ≈ $164.98 Million |
+34.18% |
| 2012-12-31 | ₩181.43 Billion ≈ $122.95 Million |
+9.22% |
| 2011-12-31 | ₩166.11 Billion ≈ $112.57 Million |
+39.65% |
| 2009-12-31 | ₩118.95 Billion ≈ $80.61 Million |
-- |
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more